Small Cell Lung Cancer in the Course of Idiopathic Pulmonary Fibrosis-Case Report and Literature Review

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2022 Jul 25

PMID 35877261

Authors

Maria Grodkiewicz

Pawel Koziel

Izabela Chmielewska

Marta Adamczyk Korbel

Janusz Milanowski

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis is a poorly prognosed form of progressive interstitial pneumonia. Patients with IPF have a significantly increased risk of developing lung cancer, which further worsens the course of the disease. The most common histological types of LC among patients with IPF are squamous cell carcinoma and adenocarcinoma. Furthermore, all LC treatment modalities can lead to developing an acute IPF exacerbation. In this report, we present a rare case of coexistence of IPF and small cell lung cancer in a 76-year-old patient with chronic obstructive pulmonary disease, and a former smoker. For over 2 years, the patient was treated with an anti-fibrotic drug-pirfenidone, which slowed down the progression of IPF. Unfortunately, after being diagnosed with an active SCLC, the patient was excluded from further participation in the pirfenidone drug program. SCLC is characterized by high aggressiveness, rapid growth and high metastatic potential; therefore, it is necessary to apply antitumor treatment as soon as possible. The described patient was treated with carboplatin-etoposide chemotherapy. Early treatment tolerance was good and after two cycles of cytotoxic treatment, a partial response was present in CT. The presented case emphasizes the need for further research to determine the treatment regimens in patients with coexisting IPF and LC and the appropriateness of antifibrotic treatment in them. In addition, it can help to choose the treatment method for similar patients, indicating a combination of carboplatin and etoposide as an effective and, at the same time, relatively safes method in terms of the risk of IPF's exacerbation.

Citing Articles

Interstitial Lung Diseases and Non-Small Cell Lung Cancer: Particularities in Pathogenesis and Expression of Driver Mutations.

Sampsonas F, Bosgana P, Bravou V, Tzouvelekis A, Dimitrakopoulos F, Kokkotou E Genes (Basel). 2024; 15(7).

PMID: 39062713 PMC: 11276289. DOI: 10.3390/genes15070934.

Idiopathic Pulmonary Fibrosis Comorbid With Mediastinal Small Cell Carcinoma: A Clinical Dilemma.

Shakir M, Basit S, Ray B, Zaidi S, Chaudhary T, Amjad M Cureus. 2024; 16(2):e53578.

PMID: 38449967 PMC: 10915904. DOI: 10.7759/cureus.53578.

Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and Their Association with Lung Cancer by Bioinformatics Analysis.

Velazquez-Enriquez J, Reyes-Avendano I, Santos-Alvarez J, Reyes-Jimenez E, Vasquez-Garzon V, Baltierrez-Hoyos R Adv Respir Med. 2023; 91(5):407-431.

PMID: 37887075 PMC: 10604190. DOI: 10.3390/arm91050032.

References

Nathan N, Giraud V, Picard C, Nunes H, Dastot-Le Moal F, Copin B . Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum Mol Genet. 2016; 25(8):1457-67. DOI: 10.1093/hmg/ddw014. View

Lee T, Park J, Lee H, Cho Y, Yoon H, Lee J . Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med. 2014; 108(10):1549-55. DOI: 10.1016/j.rmed.2014.07.020. View

Miyazaki K, Satoh H, Kurishima K, Nakamura R, Ishikawa H, Kagohashi K . Interstitial lung disease in patients with small cell lung cancer. Med Oncol. 2009; 27(3):763-7. DOI: 10.1007/s12032-009-9283-z. View

van Moorsel C, ten Klooster L, van Oosterhout M, de Jong P, Adams H, van Es H . SFTPA2 Mutations in Familial and Sporadic Idiopathic Interstitial Pneumonia. Am J Respir Crit Care Med. 2015; 192(10):1249-52. DOI: 10.1164/rccm.201504-0675LE. View

Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X . FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer. Oncologist. 2021; 26(5):433-438. PMC: 8100557. DOI: 10.1002/onco.13752. View

Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824. PMC: 5450933. DOI: 10.1164/rccm.2009-040GL. View

Gottfried M, Bennouna J, Bondarenko I, Douillard J, Heigener D, Krzakowski M . Efficacy and Safety of Nintedanib Plus Docetaxel in Patients with Advanced Lung Adenocarcinoma: Complementary and Exploratory Analyses of the Phase III LUME-Lung 1 Study. Target Oncol. 2017; 12(4):475-485. DOI: 10.1007/s11523-017-0517-2. View

Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N . Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thorac Cancer. 2018; 9(11):1519-1521. PMC: 6209776. DOI: 10.1111/1759-7714.12853. View

Vancheri C, Failla M, Crimi N, Raghu G . Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010; 35(3):496-504. DOI: 10.1183/09031936.00077309. View

10.

Zhang X, Li W, Li C, Zhang J, Su Z . Chemotherapy in idiopathic pulmonary fibrosis and small-cell lung cancer with poor lung function. BMC Pulm Med. 2021; 21(1):122. PMC: 8051081. DOI: 10.1186/s12890-021-01489-4. View

11.

Kai Y, Matsuda M, Fukuoka A, Hontsu S, Yamauchi M, Yoshikawa M . Remarkable response of non-small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis. Thorac Cancer. 2021; 12(9):1457-1460. PMC: 8088921. DOI: 10.1111/1759-7714.13935. View

12.

Fukunaga K, Yokoe S, Kawashima S, Uchida Y, Nakagawa H, Nakano Y . Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis. Respirol Case Rep. 2018; 6(8):e00363. PMC: 6138540. DOI: 10.1002/rcr2.363. View

13.

Dabholkar S, Gao B, Chuong B . Nintedanib-A case of treating concurrent idiopathic pulmonary fibrosis and non-small cell lung cancer. Respirol Case Rep. 2022; 10(2):e0902. PMC: 8756078. DOI: 10.1002/rcr2.902. View

14.

King C, Nathan S . Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2016; 5(1):72-84. DOI: 10.1016/S2213-2600(16)30222-3. View

15.

Kreuter M, Ehlers-Tenenbaum S, Schaaf M, Oltmanns U, Palmowski K, Hoffmann H . Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc Diffuse Lung Dis. 2015; 31(4):266-74. View

16.

Kashiwabara K, Semba H, Fujii S, Tsumura S, Aoki R . Difference in benefit of chemotherapy between small cell lung cancer patients with interstitial pneumonia and patients with non-small cell lung cancer. Anticancer Res. 2015; 35(2):1065-71. View

17.

Collard H, Ryerson C, Corte T, Jenkins G, Kondoh Y, Lederer D . Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016; 194(3):265-75. DOI: 10.1164/rccm.201604-0801CI. View

18.

Minegishi Y, Kuribayashi H, Kitamura K, Mizutani H, Kosaihira S, Okano T . The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. J Thorac Oncol. 2011; 6(4):801-7. DOI: 10.1097/JTO.0b013e3182103d3c. View

19.

Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y . Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer. Clin Lung Cancer. 2011; 13(4):304-11. DOI: 10.1016/j.cllc.2011.11.001. View

20.

Martinez F, Collard H, Pardo A, Raghu G, Richeldi L, Selman M . Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017; 3:17074. DOI: 10.1038/nrdp.2017.74. View